Biotech Values

[fid]

That doesnt answer my questions.

1. From the Phase II 900 patient trial can you please explain how many patients would have had a peak CK-MB greater than or equal to 100ng/ml to put it in proper perspective and show why the failure of the primary endpt of 50ng/ml is significant?

2. From the current 3000 patient trial, how many patients would you expect to have a peak CK-MB greater than or equal to 100ng/ml?

fid